# US 2026/0176231 A1 · Lipidoids for nucleic acid transfection and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0176231 A1
- Document ID: US20260176231A1
- Status: Published application
- Kind: A1
- Application number: 19/547,184
- Filed: 2026-02-23
- Published: 2026-06-25
- Earliest claimed: 2020-09-23
- Assignees: Ustav Organicke Chemie A Biochemie Av Cr, V.V.I.
- Applicants: Ustav Organicke Chemie a Biochemie AV CR, v.v.i.
- Inventors: Petr Cígler; Klara GRANTZ SASKOVA; Vaclav VANEK; Zuzana KRUZIKOVA; Frantisek SEDLAK
- Web page: https://patentgrep.com/patent/US20260176231A1

## CPC

- C07C 233/62: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 48/0033: {the non-active part being non-polymeric}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 219/12: having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C07C 2603/74: Adamantanes
- C12N 2320/30: Special therapeutic applications
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The subject of the present invention is a lipidoid of general formula I wherein X, Y, Z and R are as defined in the claims. This lipidoid is useful as a transfection agent. The invention further describes transfection agents, transfection particles containing this lipidoid, and their use.

## Claims

### Claim 1

A lipidoid of general formula I
wherein X is selected from a group consisting of —C(═O)NH—, —C(═O)O—, —C(═S)O—, —C(═O)S—, —C(═S)S—, —C(═O)NHNH—, —CH2—, —O—, —OC(═O)—, —S—, —SC(═O)—, —NH—, —NHNH—, —NHC(═O)—, —NHNHC(═O)—, —C≡C—, —CH═CH—, a five-membered heterocycle containing at least 2 nitrogen atoms, —CH2C(═O)NH—, —CH2C(═O)O—, —CH2C(═S)O—, —CH2C(═S)S—, —CH2C(═O)NHNH—, —N═CH—, and —CH═N—;
Y is independently selected from a group consisting of alkylene chains C2-C10, wherein in the said alkylene chain, one or more —CH2— groups may optionally be replaced with one or more O or S atoms;
Z is selected from the group consisting of hydrogen, —OH, —CH2OH, —NH2, —N+(CH3)2—(CH2)3—SO3, —N+(CH3)2—(CH2)2—COO—, and —NHCH3, —N(CH3)2, —N+(CH3)3, —OCH3, —OCH2CH3, —C(═O)R1,
wherein R1 is selected from —NH2, —NH(CH2)nOH, —N[(CH2)nOH]2, —NHCH(CH2OH)2, —NHCH2CH(—OH)CH2OH, —NH(CH2)nC(═O)NH2, —N[CH2C(═O)NH2]2, —NHCH[C(═O)NH2]2, —NH(CH2)2NHC(═O)NH2,
wherein n is an integer within the range from 2 to 5;
and R are the same or different from each other, each R being independently selected from the group consisting of alkyl C8-C20, alkenyl C8-C20, and alkynyl C8-C20, wherein in the said alkyl, alkenyl or alkynyl, one or more —CH2— groups may optionally be replaced with one or more groups selected from —CH(OH)—, —OC(═O)—, —C(═O)O—, —S—S—, —C(═O)NH—, —NHC(═O)—, —O—, and —S—;
and pharmaceutically acceptable salts, addition salts and solvates thereof.

### Claim 2 (depends on 1)

The lipidoid according to claim 1, wherein Z is selected from a group consisting of hydrogen, —OH, —CH2OH, —NH2, —N+(CH3)2—(CH2)3—SO3−, —N+(CH3)2—(CH2)2—COO−, and —C(═O)R1,
wherein R1 is selected from —NH2, —NH(CH2)nOH, —N[(CH2)nOH]2, —NHCH(CH2OH)2, —NHCH2CH(OH)CH2OH, —NH(CH2)nC(═O)NH2, —N[CH2C(═O)NH2]2, —NHCH[C(═O)NH2]2, —NH(CH2)2NHC(═O)NH2,
wherein n is an integer within the range from 2 to 5.

### Claim 3 (depends on 1)

The lipidoid according to claim 1, wherein X is selected from —C(═O)NH—, a five membered heterocycle containing at least 2 nitrogen atoms, or —C(═O)O—.

### Claim 4 (depends on 1)

The lipidoid according to claim 1, wherein R is independently selected from the group consisting of C8-C20 alkyl, C8-C20 alkenyl, and C8-C20 alkynyl, wherein in the said alkyl, alkenyl or alkynyl, one or more —CH2— groups may optionally be replaced by one or more groups selected from —CH(OH)—, —OC(═O)—, and —C(═O)O—.

### Claim 5 (depends on 1)

The lipidoid according to claim 1, wherein all R in the molecule are the same, or all nitrogen atoms in the molecule are substituted identically by two identical R or two different R.

### Claim 6 (depends on 1)

A transfection agent comprising at least one lipidoid of general formula I according to claim 1 in an amount of 10 to 50 mol. %, and at least one helper lipid in a total amount of 50 to 90 mol. %.

### Claim 7 (depends on 1)

A transfection agent comprising at least one lipidoid of general formula I according to claim 1 in an amount of 15 to 30 mol. %, cholesterol in an amount of 30 to 55 mol. %, and at least one further helper lipid in an amount of 20 to 50 mol. %.

### Claim 8 (depends on 1)

A transfection particle comprising at least one lipidoid of general formula I according to claim 1, at least one nucleic acid and/or a part thereof and/or nucleic acid derivative, and preferably also at least one helper lipid.

### Claim 9 (depends on 1)

A method of treatment comprising the step of administering the lipidoid of general formula I according to claim 1 for in vitro transfection of cells or tissues with nucleic acid and/or a part thereof and/or nucleic acid derivative to a subject in need thereof.

### Claim 10 (depends on 9)

The method according to claim 9 for silencing or activating chromosomal gene(s), silencing or activating immunogens, inhibiting or activating signaling pathways, editing genome or transcriptome, or enabling the expression of the protein(s) encoded by the nucleic acid.

### Claim 11 (depends on 1)

The lipidoid of formula I according to claim 1 for use in transfecting cells or tissues with nucleic acid and/or a part thereof and/or nucleic acid derivative in vivo, preferably except for the transfection of human embryos for use in industrial or commercial purposes and except for the modification of a human germ line.

### Claim 12 (depends on 1)

The lipidoid of formula I according to claim 1 for silencing or activating chromosomal genes(s), silencing or activating immunogens, inhibiting or activating signaling pathways, editing genome or transcriptome, or enabling the expression of the protein(s) encoded by the nucleic acid.

### Claim 13 (depends on 1)

A method of administering a medicament, comprising the step of administering the lipidoid of formula I according to claim 1 for gene therapy, for the treatment of malignancies or the treatment of genetic disorders.

### Claim 14 (depends on 1)

A method of treatment comprising the step of administering the lipidoid of general formula I according to claim 1 in cosmetic preparations for delivering the active ingredient to the site of action to a subject in need thereof.
